期刊文献+

可承载CETP多肽表位的颗粒样蛋白表达载体的克隆、表达与分离纯化 被引量:1

Cloning,Expression,Separation and Purification of Particle-Like Protein Loading CETP Polypeptide Epitopes
下载PDF
导出
摘要 为了提高多肽表位的免疫原性,利用乙肝病毒核心抗原能够在体外自行组装成病毒样颗粒的特性,将人源胆固醇酯转运蛋白羧基端26个氨基酸连同大肠杆菌DnaK基因C端结构域克隆入乙肝病毒核心抗原的免疫优势决定区,并在大肠杆菌BL-21(DE3)表达,以包含体形式存在,经过洗涤、复性和分子筛纯化,获得纯度达90%以上的目的蛋白。纯化的蛋白免疫新西兰大白兔后能够诱导产生高水平的抗胆固醇酯转运蛋白的抗体,表明乙肝病毒核心抗原能够在体外自发装配成多聚体颗粒,并能够将插入其免疫优势决定区的胆固醇酯转运蛋白(CETP)多肽表位展示于颗粒表面以提高免疫原性,显示出其作为疫苗免疫载体的良好前景。 To enhance the immunity of polypeptide epitopes, the carboxyl-ter minal 26 a mino acids of human cholesteryl ester transfer protein and carboxyl-ter minal domain of DnaK gene were cloned into major immunodo minant region of hepatitis B virus core antigen (HBcAg) based on the characteristics that HBcAg can self-assemble into virus-like particles in vitro, and induce expression of the target protein in E. coli BL21(DE3) in the form of inclusion body. About 90% purity of the recombinant protein was obtained following washing, denaturing and purifying via size-exclusion chromatography. The high level anti-CETP antibody was induced after New Zealand White Rabbits were inoculated with purified recombinant protein, which demonstrated that HBcAg can improve the immunity of CETP polypeptide epitopes merged into major immunodo minant region of HBcAg and displayed on the surface of HBcAg which can self-assemble into polymer particles in vitro. It indicates that the polypeptide carrier is full of promise for vaccination.
出处 《药物生物技术》 CAS CSCD 2006年第4期237-243,共7页 Pharmaceutical Biotechnology
基金 国家自然科学基金资助项目(No.30500458 No.30270298)
关键词 乙肝病毒核心抗原 病毒样颗粒 DnaK基因 胆固醇酯转运蛋白 包含体 纯化 Hepatitis B virus core antigen, Virus-like particle, DnaK gene, Cholesteryl ester transfer protein, Inclusion body Purification
  • 相关文献

参考文献14

  • 1Rittershaus C,Miller D P,Thomas L J,et al.Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aor tic lesions in a rabbit model of atherosclerosis[J].Arterioscler Thromb Vasc Biol,2 000,20(9):2106.
  • 2Gaofu Q,Dan M,Jie W,el al.Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal ad ministration of a 26-a mino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants[J].Vaccine,2004,22(23-24):3187.
  • 3Gaofu Q,Jun I,Xin Y,el al.Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti CETP antibodies and reducing aortic lesions in vivo[J].J Cardiovasc Pharmacol,2005,45 (6):591.
  • 4Gaofu Q,Jun L,Xin Z,el al.Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model[J].Life Sciences,2005,77(21):2690.
  • 5Clarke B E,Brown A L,Grace K G,et al.Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria[J].J Gen Viral,1990,71(Pt 5):1109.
  • 6萨姆布鲁克J 弗里奇EF 曼尼阿蒂斯 金冬雁 黎孟枫 译.分子克隆实验指南[M](第二版)[M].北京:科学出版社,1992..
  • 7Pumpens P,Grens E.HBV core particles as a carrier for B cell/T cell epitopes[J].Intervirology,2001,44(2-3):98.
  • 8Sabine K,Gertrud B,Michael N.Mapping of Homologous Interaction Sites in the Hepatitis B Virus Core Protein[J].J Virol,1998,72(6):4997.
  • 9Schodel F,Moriarty A M,Peterson D L,et al.The position of heterologous epitopes inserted in heaptitis B virus core particles deter mines their immunogenicity[J].J Virol,1992,66(1):106.
  • 10Schodel F,Peterson D,Milich D.Hepatitis B virus core and e antigen:Immune recognition and use as a vaccine carrier moiety[J].Interviology,1996,39(1-2):104.

共引文献2

同被引文献19

  • 1Durrington P. HDL in risk prediction and its direct and indirect involvement in atherogenesis [J]. Atherosclerosis, 2002, 3(4): 3(Suppl).
  • 2Asztalos BF, Schaefer EJ. HDL in atherosclerosis: actor or bystander [J]. Atherosclerosis, 2003, 4(1) : 21(Suppl).
  • 3Barter PJ, Rye KA. Cholesteryl ester transfer protein: its role in plasma lipid transport [J]. Clin Exp Pharmacol Physiol, 1994, 21:663.
  • 4Tall AR. Plasma cholesteryl ester transfer protein and high- density lipoproteins: new insights from molecular genetic studies[J]. J Intern Med, 1995, 237:5.
  • 5Barter J. CETP and atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2000, 20:2029.
  • 6Rittersbaus CW, Miller DP, Thomas LJ, et al. Vaccine-in duced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis [J]. Arterioscler Thromb Vase Biol, 2000, 20:2106.
  • 7Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis[J]. Arterioscler Thomb Vasc Biol , 2003, 23:160.
  • 8Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults [J]. Atherosclerosis, 2003, 169:113.
  • 9Parini P, Rudel LL. Is There a Need for Cholesteryl Ester Transfer Protein Inhibition[J]. Arterioscler Thromb Vasc Biol, 2003, 23:374.
  • 10Qi GF, Mao D, Wu J, et al. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants [J]. Vaccine, 2004, 22(23 - 24) :3187.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部